sublingual immunotherapy peanut extract + glucopyranosyl lipid a

This is a **combination immunotherapy drug** consisting of peanut allergen extract delivered by sublingual immunotherapy (SLIT) and the adjuvant **glucopyranosyl lipid A (GLA)**, a synthetic Toll-like receptor 4 (TLR4) agonist. The combination aims to desensitize patients with peanut allergy and potentially enhance immune modulation by shifting responses from a pathological Th2 allergy profile to a protective Th1 profile and increasing regulatory T cell activity. GLA acts as an immunostimulatory adjuvant, enhancing antigen presentation and promoting Th1-biased immune responses, reducing allergic inflammation and allergy-associated cytokines such as IL-5, and increasing IFN-γ. This combination leverages both the established efficacy of SLIT for allergic desensitization and the immune-boosting effects of a TLR4 agonist. This drug is mainly in preclinical or early clinical investigation stages for **peanut allergy** and potentially other food allergies, but specific clinical trials in humans using the sublingual route and combining peanut extract with GLA are not yet published as of current data[1][2].

Other names

peanut SLIT + GLApeanut sublingual immunotherapy + GLA